William Blair Downgrades Silence Therapeutics (SLN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts SLN Hot Sheet
Price: $19.80 +0.46%
Rating Summary:
5 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
5 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
William Blair analyst Myles Minter downgraded Silence Therapeutics (NASDAQ: SLN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Silence Therapeutics click here. For more ratings news on Silence Therapeutics click here.
Shares of Silence Therapeutics closed at $8.68 yesterday.
You May Also Be Interested In
- Goldman Sachs Downgrades Bicara Therapeutics Inc (BCAX) to Sell, 'Competitive Pressure In High Gear'
- Baird Downgrades Instacart (CART) to Neutral
- CLSA Downgrades Delta Electronics Thailand PCL (DELTA:TB) to Outperform (2)
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
